Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Grover NS, Park SI (2015) Novel targeted agents in hodgkin and non-Hodgkin lymphoma therapy. Pharmaceuticals (Basel, Switzerland) 8:607–636
2. Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ et al (2020) Advances in targeted therapy for malignant lymphoma. Signal Transduct Target Ther 5:15
3. Abodunrin FO, Akinyemi OA, Ojo AS, Elleissy Nasef K, Haupt T, Oduwole A et al (2022) Racial disparities in survival among non-Hodgkin lymphoma patients: an analysis of the SEER database (2007–2015). Cureus 14:e25867
4. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P (2021) Epidemiology of non-Hodgkin’s lymphoma. Med Sci (Basel, Switzerland) 9(1):5
5. Liu W, Wu M, Xie Y, Zhang C, Ping L, Feng F et al (2021) Autologous hematopoietic stem cell transplantation with inadequate stem cell dose in patients with non-Hodgkin lymphoma. Leuk Lymphoma 62:323–329